179 related articles for article (PubMed ID: 32169921)
1. Initial Clinical Results of a Novel Immuno-PET Theranostic Probe in Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer.
Rousseau C; Goldenberg DM; Colombié M; Sébille JC; Meingan P; Ferrer L; Baumgartner P; Cerato E; Masson D; Campone M; Rauscher A; Fleury V; Labbe C; Chauvet AF; Fresnel JS; Toquet C; Barbet J; Sharkey RM; Campion L; Kraeber-Bodéré F
J Nucl Med; 2020 Aug; 61(8):1205-1211. PubMed ID: 32169921
[TBL] [Abstract][Full Text] [Related]
2. Promising clinical performance of pretargeted immuno-PET with anti-CEA bispecific antibody and gallium-68-labelled IMP-288 peptide for imaging colorectal cancer metastases: a pilot study.
Touchefeu Y; Bailly C; Frampas E; Eugène T; Rousseau C; Bourgeois M; Bossard C; Faivre-Chauvet A; Rauscher A; Masson D; David A; Cerato E; Carlier T; Sharkey RM; Goldenberg DM; Barbet J; Kraeber-Bodere F; Bodet-Milin C
Eur J Nucl Med Mol Imaging; 2021 Mar; 48(3):874-882. PubMed ID: 32820369
[TBL] [Abstract][Full Text] [Related]
3. Immuno-PET Using Anticarcinoembryonic Antigen Bispecific Antibody and 68Ga-Labeled Peptide in Metastatic Medullary Thyroid Carcinoma: Clinical Optimization of the Pretargeting Parameters in a First-in-Human Trial.
Bodet-Milin C; Faivre-Chauvet A; Carlier T; Rauscher A; Bourgeois M; Cerato E; Rohmer V; Couturier O; Drui D; Goldenberg DM; Sharkey RM; Barbet J; Kraeber-Bodere F
J Nucl Med; 2016 Oct; 57(10):1505-1511. PubMed ID: 27230928
[TBL] [Abstract][Full Text] [Related]
4. Anti-CEA Pretargeted Immuno-PET Shows Higher Sensitivity Than DOPA PET/CT in Detecting Relapsing Metastatic Medullary Thyroid Carcinoma: Post Hoc Analysis of the iPET-MTC Study.
Bodet-Milin C; Faivre-Chauvet A; Carlier T; Ansquer C; Rauscher A; Frampas E; Toulgoat F; Masson D; Bourgeois M; Cerato E; Rohmer V; Couturier O; Drui D; Goldenberg DM; Sharkey RM; Barbet J; Kraeber-Bodere F
J Nucl Med; 2021 Sep; 62(9):1221-1227. PubMed ID: 33547213
[TBL] [Abstract][Full Text] [Related]
5. Comparison of an Affibody-based Molecular Probe and
Guo X; Zhou N; Liu J; Ding J; Liu T; Song G; Zhu H; Yang Z
Radiology; 2024 Jun; 311(3):e232209. PubMed ID: 38888484
[TBL] [Abstract][Full Text] [Related]
6. Functional imaging of human epidermal growth factor receptor 2-positive metastatic breast cancer using (64)Cu-DOTA-trastuzumab PET.
Mortimer JE; Bading JR; Colcher DM; Conti PS; Frankel PH; Carroll MI; Tong S; Poku E; Miles JK; Shively JE; Raubitschek AA
J Nucl Med; 2014 Jan; 55(1):23-9. PubMed ID: 24337604
[TBL] [Abstract][Full Text] [Related]
7.
Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
[TBL] [Abstract][Full Text] [Related]
8. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
9. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
[TBL] [Abstract][Full Text] [Related]
10. Association between partial-volume corrected SUVmax and Oncotype DX recurrence score in early-stage, ER-positive/HER2-negative invasive breast cancer.
Lee SH; Ha S; An HJ; Lee JS; Han W; Im SA; Ryu HS; Kim WH; Chang JM; Cho N; Moon WK; Cheon GJ
Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1574-84. PubMed ID: 27209424
[TBL] [Abstract][Full Text] [Related]
11.
Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837
[TBL] [Abstract][Full Text] [Related]
12. Human Epidermal Growth Factor Receptor 2-Targeting [
Alhuseinalkhudhur A; Lindman H; Liss P; Sundin T; Frejd FY; Hartman J; Iyer V; Feldwisch J; Lubberink M; Rönnlund C; Tolmachev V; Velikyan I; Sörensen J
J Nucl Med; 2023 Sep; 64(9):1364-1370. PubMed ID: 37442602
[TBL] [Abstract][Full Text] [Related]
13. Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts.
Schoffelen R; Sharkey RM; Goldenberg DM; Franssen G; McBride WJ; Rossi EA; Chang CH; Laverman P; Disselhorst JA; Eek A; van der Graaf WT; Oyen WJ; Boerman OC
Mol Cancer Ther; 2010 Apr; 9(4):1019-27. PubMed ID: 20354120
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
[TBL] [Abstract][Full Text] [Related]
15.
Wu J; Wang S; Zhang X; Teng Z; Wang J; Yung BC; Niu G; Zhu H; Lu G; Chen X
J Nucl Med; 2018 Dec; 59(12):1809-1816. PubMed ID: 29700127
[No Abstract] [Full Text] [Related]
16. Impact of
Zhou N; Liu C; Guo X; Xu Y; Gong J; Qi C; Zhang X; Yang M; Zhu H; Shen L; Yang Z
Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):161-175. PubMed ID: 32564171
[TBL] [Abstract][Full Text] [Related]
17. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.
Melsaether AN; Raad RA; Pujara AC; Ponzo FD; Pysarenko KM; Jhaveri K; Babb JS; Sigmund EE; Kim SG; Moy LA
Radiology; 2016 Oct; 281(1):193-202. PubMed ID: 27023002
[TBL] [Abstract][Full Text] [Related]
19. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
Zhang X; Wu F; Han P
Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
[TBL] [Abstract][Full Text] [Related]
20. Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues.
Pace L; Nicolai E; Luongo A; Aiello M; Catalano OA; Soricelli A; Salvatore M
Eur J Radiol; 2014 Feb; 83(2):289-96. PubMed ID: 24331845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
